Quimioterapia en linfoma y su estrecha relación con el virus de la inmunodeficiencia humana /síndrome de inmunodeficiencia adquirida

Chemotherapy in lymphoma and its close relation with human immunodeficiency virus /acquired immunodeficiency syndrome

El virus de la inmunodeficiencia humana (VIH) ha estado en nuestra sociedad durante muchos años y los casos han aumentado con el paso del tiempo. La inmunosupresión y el síndrome de inmunodeficiencia adquirida (SIA) predisponen en gran parte al desarrollo de diferentes enfermedades, como el linfoma. Objetivo: realizar una revisión acerca de la quimioterapia en el linfoma asociado con el virus de la inmunodeficiencia humana y el síndrome de inmunodeficiencia adquirida, y su predisposición a sufrir más enfermedades oportunistas. Métodos: se realizó una revisión de la literatura en las bases de datos PubMed y ScienceDirect, con los descriptores “infecciones”, “linfoma”, “neoplasias”, “quimioterapia”, “serodiagnóstico del SIDA”, en inglés y español, seleccionando 10 artículos relacionados. Conclusión: la inmunosupresión que genera este virus puede predisponer en gran medida al desarrollo de muchas neoplasias en especial el linfoma. A pesar de que la quimioterapia es el tratamiento más efectivo en este tipo de pacientes, exacerba la condición de base de las personas y los hace más susceptibles a padecer infecciones oportunistas, las cuales pueden empeorar su situación, considerando así la quimioterapia como un factor de riesgo.

1. Wang Z, Zhang R, Liu L, Shen Y, Chen J, Qi T, et al. Incidence and spectrum of infections among HIV/AIDS patients with lymphoma during chemotherapy. J Infect Chemother. 2021; (10):1459-64. doi: 10.1016/j.jiac.2021.06.012.
2. Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495-e504. doi: 10.1016/S2352-3018(17)30125-X.
3. Ramorola BR, Goolam-Hoosen T, Alves de Souza Rios L, Mowla S. Modulation of Cellular MicroRNA by HIV-1 in Burkitt Lymphoma Cells-A Pathway to Promoting Oncogenesis. Genes (Basel). 2021;12(9):1302. doi:10.3390/genes12091302.
4. Yarchoan R, Uldrick TS. HIV-Associated Cancers and Related Diseases. N Engl J Med. 2018;378(11):1029-1041. doi: 10.1056/NEJMra1615896.
5. Antel K, Chetty D, Oosthuizen J, Mohamed Z, Van der Vyver L, Verburgh E. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients. Pathology. 2021; 53(5):628-34. doi: 10.1016/j.pathol.2020.11.004.
6. Yarchoan R, Uldrick TS. HIV-Associated Cancers and Related Diseases. N Engl J Med. 2018; (11):1029-41. doi: 10.1056/NEJMra1615896.
7. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. doi: 10.1182/blood-2016-01-643569.
8. Re A, Cattaneo C, Rossi G. Hiv and Lymphoma: from Epidemiology to Clinical Management. Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019004. doi: 10.4084/MJHID.2019.004.
9. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013 ;122(19):3251-62. doi: 10.1182/blood-2013-04-498964.
10. Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, et al. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. Front Immunol. 2021;12:700045. doi: 10.3389/fimmu.2021.700045.
11. Navarro JT, Moltó J, Tapia G, Ribera JM. Hodgkin Lymphoma in People Living with HIV. Cancers (Basel). 2021 ;13(17):4366. doi: 10.3390/cancers13174366.
12. Horner MJ, Shiels MS, Pfeiffer RM, Engels EA. Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001-2015. Clin Infect Dis. 2021;72(9):e224-e231. doi: 10.1093/cid/ciaa1016.
13. Kimani SM, Painschab MS, Horner MJ, Muchengeti M, Fedoriw Y, Shiels MS, et al. Epidemiology of haematological malignancies in people living with HIV. Lancet HIV. 2020 ;7(9):e641-e651. doi: 10.1016/S2352-3018(20)30118-1.
14. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014 Mar ;28(6):881-90. doi: 10.1097/QAD.0000000000000163.
15. Strosberg C, Sagatys E. Primary anaplastic large cell lymphoma of the CNS as initial presentation of HIV infection: A case report. Human Pathology: Case reports. 2021; 24 (200493-523).
16. Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med. 2000 Sep 4;192(5):637-46. doi: 10.1084/jem.192.5.637.
17. Hanna J, Hossain GS, Kocerha J. The Potential for microRNA Therapeutics and Clinical Research. Front Genet. 2019 May 16;10:478. doi: 10.3389/fgene.2019.00478.
18. Gebauer N, Witte HM, Merz H, Oschlies I, Klapper W, Caliebe A, Tharun L, Spielmann M, von Bubnoff N, Feller AC, Murga Penas EM. Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma. Blood Adv. 2021:bloodadvances.2021004635. doi: 10.1182/bloodadvances.2021004635.
19. Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018; 103(5):857-864. doi: 10.3324/haematol.2017.180893.
20. Casimiro LC, Mauro GP, Medici CTM, Weltman E. Survival and consolidative radiotherapy in patients living with HIV and treated for diffuse large B-cell lymphoma. Rep Pract Oncol Radiother. 2020; 25(6):956-960. doi: 10.1016/j.rpor.2020.09.004.
21. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016; 128(8):1050-8. doi: 10.1182/blood-2015-08-664706.
22. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005; 105(2):874-8. doi: 10.1182/blood-2004-04-1532.
23. Simonelli C, Zanussi S, Pratesi C, Rupolo M, Talamini R, Caffau C, et al. Immune Recovery After Autologous Stem Cell Transplantation Is Not Different for HIV-Infected Versus HIV-Uninfected Patients With Relapsed or Refractory Lymphoma. Clin Infect Dis. 2010; 50(12):1672–9. doi: 10.1086/652866
24. Re A, Gini G, Rupolo M, Levis A, Bandera A, Liberati AM, et al. Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. Bone Marrow Transplant. 2018; 53(2):228-230. doi: 10.1038/bmt.2017.230.
25. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4.
26. De Matos A, Lopes SB, Serra JE, Ferreira E, da Cunha JS. Mortality predictive factors of people living with human immunodeficiency virus and bloodstream infection. Int J Infect Dis. 2021 Sep;110:195-203. doi: 10.1016/j.ijid.2021.06.032
27. Ortega M, Almela M, Soriano A, Marco F, Martínez JA, Muñoz A, Peñarroja G, Mensa J. Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality. Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):969-76. doi: 10.1007/s10096-008-0531-5.
28. Ohmoto A, Fuji S. Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. Blood Rev. 2021;46:100738. doi: 10.1016/j.blre.2020.100738.
29. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799. doi: 10.1200/JCO.18.01994.
30. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(30):3043-3054. doi: 10.1200/JCO.18.00374.